Somatostatin Analogue Use to treat visual field loss in acromegaly newly diagnosed in pregnancy
I. Frizelle, D. J. O’Halloran

1. 11/40 gestation
Presenting with headache- underwent CT brain. Pituitary mass- MRI pituitary performed.

2. MRI Pituitary


4. Patient opted for medical therapy: Octreotide 100 micrograms TDS commenced.

5. Pre: Post:

Improvement in visual field 2/52 after treatment start date.

6. Further deterioration of visual fields requiring dose titration to 200 micrograms tds at 24/40.

7. Foetal growth on 50th centile throughout pregnancy
Elective caesarean at 34/40
Uncomplicated
Baby girl 3.2Kg
APGAR score 9

8. Post partum labs
Random GH 9.8 micrograms/L
IGF-1 460 micrograms/L (age- specific ref range

9. Points of interest
○ Fertility despite active undiagnosed disease.
○ Successful treatment of visual field loss.
○ Optimal obstetric outcome.

Post presented at: Neuroendocrinology and pituitary